KRAS and neoplasm: Genomic landscape studies have indicated that activation of the tumor-driving K-RAS/EGFR pathway is highly prevalent in high-grade, locally advanced, relapsed, and chemo-refractory TNBC [208,268,269,270,271,272,273,274].